SCHEMBL467699

SCHEMBL467699

O/N=C/Cc1ccc(O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.46
ESR2 Q92731 2/20 0.46
ABAT P80404 1/20 0.42
CA2 P00918 4/20 0.41
CTBP2 P56545 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
IDO1 P14902 2/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
SLC6A2 P23975 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTR3A P46098 1/20 0.39
BACE1 P56817 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TRPA1 O75762 1/20 0.39
BLM P54132 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934459 1.00 ESR1 (0.46) ESR1ESR2ABATCA2CTBP2
SCHEMBL467700 1.00 ESR1 (0.46) ESR1ESR2ABATCA2CTBP2
SCHEMBL25620242 0.83 ESR1 (0.48) ESR1ESR2ABATCA2KDM4E
SCHEMBL448421 0.79 ESR1 (0.55) ESR1ESR2ABATCA2KDM4E
SCHEMBL448422 0.79 ESR1 (0.55) ESR1ESR2ABATCA2KDM4E
SCHEMBL5898755 0.79 IDO1 (0.45) CTBP2ALDH1A1IDO1CYP2C19HTR3A
SCHEMBL4618746 0.79 ALDH1A1 (0.44) KDM4EALDH1A1IDO1L3MBTL1KMT2A
SCHEMBL9705001 0.79 TRPA1 (0.47) CTBP2IDO1TAAR1TRPA1KMT2A
SCHEMBL10070249 0.79 ESR1 (0.44) ESR1ESR2ABATCA2KDM4E
SCHEMBL9705002 0.79 TRPA1 (0.47) CTBP2IDO1TAAR1TRPA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486404-A1 METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY Wisconsin Alumni Research Foundation (US) 2012-08-15 EP claimed
WO-2011044253-A1 METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-04-14 WO claimed
US-20110081675-A1 Metabolic Biomarkers Of Drug-Induced Cardiotoxicity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-04-07 US claimed
US-20030166202-A1 P450 Monooxygenases of the cyp79 family ROYAL VETERINARY AND AGRICULTURAL UNIVERSITY (DK) 2003-09-04 US claimed
EP-1246906-A2 P450 MONOOXYGENASES OF THE CYP79 FAMILY Syngenta Participations AG (CH) 2002-10-09 EP claimed
WO-2001051622-A2 P450 MONOOXYGENASES OF THE CYP79 FAMILY SYNGENTA PARTICIPATIONS AG (CH) 2001-07-19 WO claimed
WO-2025093687-A1 METHODS AND MATERIALS FOR IMPROVING PRODUCTION OF COMPOUNDS OF CYP450 PATHWAYS UNIVERSITY OF COPENHAGEN (DK) 2025-05-08 WO disclosed
US-12137687-B2 Method for inducing acquired resistance in a plant HEINRICH HEINE UNIVERSITAET DUESSELDORF (DE) 2024-11-12 US disclosed
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM BP CORP NORTH AMERICA INC (US) 2015-08-27 US disclosed
US-20150232889-A1 Method of Producing a Low Molecular Weight Organic Compound in a Cell EVOLVA SA (CH) 2015-08-20 US disclosed
US-8986950-B2 Method of producing a low molecular weight organic compound in a cell EVOLVA SA (CH) 2015-03-24 US disclosed
US-8986950-B2 Method of producing a low molecular weight organic compound in a cell EVOLVA SA (CH) 2015-03-24 US disclosed
US-8962800-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2015-02-24 US disclosed
US-6133417-A ENZYME CATALYZES CONVERSION OF AMINO ACID TO CORRESPONDING N-HYDROXYAMINO ACID AND THEN INTO CORRESPONDING OXIME; FOR TRANSGENIC PLANTS RESISTANT TO INSECTS, ACARIDS, OR NEMATODES OR PLANTS WITH IMPROVED NUTRITIVE VALUE NOVARTIS FINANCE CORPORATION (US) 2000-10-17 US disclosed
US-6020288-A PLANT GROWTH AGENT NONOMURA ARTHUR M (US) 2000-02-01 US disclosed
EP-0970191-A2 CYTOCHROME P450 MONOOXYGENASES Novartis AG (CH) 2000-01-12 EP disclosed
US-5882851-A DNA MOLECULE CODING FOR A CYTOCHROME P-450 MONOOXYGENASE THAT CATALYZES THE CONVERSION OF AN AMINO ACID TO THE CORRESPONDING N-HYDROXYAMINO ACID AND THE CONVERSION OF SAID N-HYDROXYAMINO ACID TO THE CORRESPONDING OXIME NOVARTIS FINANCE CORPORATION (US) 1999-03-16 US disclosed
WO-1998040470-A2 CYTOCHROME P450 MONOOXYGENASES NOVARTIS AG (CH) 1998-09-17 WO disclosed
EP-0733112-A1 CYTOCHROME P-450 MONOOXYGENASES Novartis AG (CH) 1996-09-25 EP disclosed
WO-1995016041-A1 CYTOCHROME P-450 MONOOXYGENASES CIBA-GEIGY AG (CH) 1995-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM POLN, POLM, POLI ESR1 4074/4885ESR2 4446/4885ABAT 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.